Pharmacokinetic Study in Healthy Lactating Women Exposed to Ibrexafungerp
Status:
COMPLETED
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
This is a pharmacokinetic evaluation of lactating women after receiving two doses of Ibrexafungerp. The study population included healthy lactating females who were at least 10 days postpartum with a fully established milk supply and were between the ages of 18 and 50 years at the time of screening